Revolution Medicines Closes $1.65B Equity Offering, Secures $500M Convertible Notes for $2.14B Total Capital Raise
RVMD has more than doubled off its 52-week low of $34 on elevated volume (2.0× avg).
Summary
Revolution Medicines, Inc. announced the closing of its upsized $1.65 billion common stock offering and provided an update on its $500 million convertible senior notes offering, bringing the total capital raise to approximately $2.14 billion.
Key Events · Financing and Capital Events · RVMD
-
Equity Offering Finalized and Closed
The company closed its common stock offering on April 16, 2026, issuing 12,147,887 shares (including the full exercise of underwriters' option) at $142.00 per share, generating approximately $1.65 billion in net proceeds.
-
Convertible Note Offering Details Confirmed
A concurrent offering of $500 million aggregate principal amount of 0.50% Convertible Senior Notes due 2033 was agreed upon, with expected net proceeds of approximately $486.8 million and an anticipated closing date of April 17, 2026.
-
Significant Capital Infusion for Pipeline
The combined offerings are expected to raise approximately $2.14 billion in total net proceeds, which will be used for general corporate purposes, including funding research and development, and potential commercialization of product candidates.
-
Strategic Timing Near 52-Week Highs
The capital raise was strategically timed following positive clinical trial results announced on April 13, 2026, and executed while the stock is trading near its 52-week high, demonstrating an opportunistic approach to funding growth.
Analysis · RVMD · Life Sciences
Revolution Medicines, Inc. has successfully closed its upsized common stock offering, raising approximately $1.65 billion in net proceeds. Concurrently, the company entered into an agreement for a $500 million convertible senior notes offering, expected to close on April 17, 2026, bringing the total capital secured from these concurrent offerings to approximately $2.14 billion. This substantial capital infusion follows closely on the heels of highly positive clinical trial results announced on April 13, 2026, positioning the company to aggressively fund its research and development pipeline and potential commercialization efforts. The equity offering was priced at $142.00 per share, a slight discount to the last reported sale price of $147.01 on April 14, 2026, but the upsized nature and timing near the company's 52-week high indicate strong market demand and a strategic move to capitalize on favorable conditions. Officers and directors are subject to a 45-day lock-up period, which is standard for such offerings.
How filings like this one have moved
In the 30 days to Sep 14, 2026, 41.1% of the 372 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.38%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RVMD was trading at $148.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.6B. The 52-week trading range was $34.00 to $155.70. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.